AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

20.03USD
11 Jul 2014
Price Change (% chg)

$0.06 (+0.30%)
Prev Close
$19.97
Open
$19.91
Day's High
$20.31
Day's Low
$19.79
Volume
65,707
Avg. Vol
131,114
52-wk High
$28.30
52-wk Low
$16.49

AMAG.OQ

Chart for AMAG.OQ

About

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection for Intravenous (IV), used to treat iron deficiency anemia (IDA), in adult patients with chronic kidney disease (CKD), and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells... (more)

Overall

Beta: 0.12
Market Cap (Mil.): $438.96
Shares Outstanding (Mil.): 21.92
Dividend: --
Yield (%): --

Financials

  AMAG.OQ Industry Sector
P/E (TTM): -- 35.37 35.77
EPS (TTM): -0.59 -- --
ROI: -4.05 19.00 18.27
ROE: -7.07 19.78 19.16
Search Stocks

Swiss stocks - Factors to watch on April 1

ZURICH, April 1 - Swiss stocks were expected to open higher on Tuesday, taking their cue from gains in Asian and U.S. stocks overnight and with investors set to focus on a raft of manufacturing data from Europe and the United States later in the day.

01 Apr 2014

FDA rejects wider use of Amag anemia drug; shares slide

- Amag Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected its application for wider use of its iron deficiency drug due to safety concerns and asked for more trial data, sending its shares down as much as 15 percent.

22 Jan 2014

UPDATE 2-FDA rejects wider use of Amag anemia drug; shares slide

Jan 22 - Amag Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected its application for wider use of its iron deficiency drug due to safety concerns and asked for more trial data, sending its shares down as much as 15 percent.

22 Jan 2014

FDA rejects wider use of Amag's anemia drug

Jan 22 - Amag Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected its application for a wider use of its iron deficiency drug, sending its shares down 18 percent in premarket trade.

22 Jan 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,723 +60.00
Sanofi SA (SASY.PA) €76.30 +0.49
Fresenius Medical Care AG & Co. KGaA (FMEG.DE) €49.72 -0.19
Galenica AG (GALN.S) CHF854.00 +3.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks